Zimig 250mg Tablet contains Terbinafine 250mg, an antifungal agent indicated for the treatment of various fungal infections. Terbinafine belongs to the allylamine class and exerts its effect by inhibiting the enzyme squalene epoxidase, which is crucial in the biosynthesis of ergosterol, an essential component of fungal cell membranes. This inhibition leads to the accumulation of squalene within the fungal cell, resulting in cell death. Zimig 250mg is primarily prescribed for dermatophytic infections such as tinea corporis, tinea cruris, tinea pedis, and onychomycosis caused by susceptible strains of dermatophytes. The tablet is administered orally, ensuring systemic distribution and effective penetration into skin, hair, and nails. It is generally well tolerated; however, patients should be monitored for potential adverse effects including gastrointestinal disturbances, headache, and rare hepatotoxicity. Liver function tests are recommended prior to and during prolonged therapy. Zimig 250mg should be used with caution in patients with pre-existing liver conditions and is contraindicated in individuals with known hypersensitivity to terbinafine or any tablet excipients. Proper adherence to prescribed dosage and duration is essential to achieve optimal therapeutic outcomes and minimize the risk of resistance development.